한국어
Quantus

S.Biomedics

A304360 · KOSDAQ
₩19,210+3.28%
2026-08-25 close

S.Biomedics — pricey right now, or cheap? And what signals are flashing today?

The grade and valuation bands are below — free to read.

Loading chart…
Close
AI Insight

Why these signals fired — only backtest-proven edge, told honestly

Why this signalSignal guide

Moving-average alignment
No

No active signal.

Explore this stock further
Review signal, financial and filing context in chat
Explore in chat →

New high + volume — the real recordrecord · not a prediction

Not this one stock, but every new-high-plus-volume pick we actually published (Korea market). When this stock flashes the signal, it is treated by the same rule.(as of 2026-08-25)

Last 30 sessions
402 picks
Next-day win rate
51.6%
Avg next-day
-0.06%
vs market
-0.24%p

Beat the market on 45.3% of picks (each pick vs its own day’s market average).

Recent publish days (next-day win rate)
08-23 60%08-21 36.4%08-20 44.4%08-19 0%08-18 27.3%08-14 23.1%08-13 41.7%08-12 70%08-11 77.8%08-10 22.2%08-07 61.5%08-06 27.3%
This stock has not flashed this signal recently — the record above is the signal’s own, not this stock’s.

Entry is the latest close at publish time; next-day is the following close. “Market” is the equal-weighted average of every stock in the same market that day; delisted names are excluded from both. Fees, taxes and slippage are not included. An observed record over a short window, not a pre-registered backtest. Not investment advice.

Trade plan

Decide the exit before you enter. Set what you are willing to lose first, and the share count follows — so you know the worst case before you buy.

Fill entry, stop, account size and risk percent to get a share count. The stop must sit below the entry.

This is a calculator, not advice, and it does not promise any outcome. You choose the stop and target — the button values (ATR, recent low/high) are observations from past prices. Actual fills depend on the order book and liquidity.

Valuation Grades

Relative to 292 건강관리 peers · not investment advice

F
Overall: 건강관리 272/292 · top 93%
Factor composite · relative position in sector

Valuation in its own history

PER — · PBR 19.35 — own history (2023-05~) percentiles 53/100 · —/100

PER53/100
PBR—/100

Higher indicates lower valuation relative to its history (based on earnings and book yields).

Earnings percentiles can fluctuate for cyclical companies (including loss periods), so the book basis is shown alongside. Companies with large share buybacks can have structurally high PBR. Factual information, not investment advice.

Financial safety

Reference indicatorAs of 2024
Distress zoneFinancial-metric reference signal
Altman Z'' zoneZ'' -3.32
Distress
Grey
Safe
The marker shows the current Z'' value within the displayed zones.
Altman Z''
-3.32
Beneish M-Score
-2.84

No statistical flag

Sloan accrual
-5.20%

부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.

Factual information, not investment advice.

Earnings quality · Piotroski F-Score

5/9Moderate

Piotroski measures year-over-year financial improvement, not absolute quality.

Financial improvement score5/9

Profitability

  • Positive ROANot passed
  • Positive OCFNot passed
  • Improving ΔROAPass
  • Accruals (OCF > net income)Pass

Leverage & liquidity

  • Lower debtPass
  • Higher current ratioPass
  • No new sharesPass

Efficiency

  • Higher gross marginNot passed
  • Higher asset turnoverNot passed

Calculation note: F7(신주)은 equity/asset 유지로 근사

Already-stable companies may score lower when year-over-year improvement is limited.

Factual information, not investment advice.

Forensic signals

Anomaly and structural signals observed in the financial statements.

Revenue qualityDanger

매출 흑자인데 영업CF 적자 (OCF/매출 -25%). 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Factual information, not investment advice.

Industry structure

KRAs of 2026-08-25

건강관리

This stock is in 건강관리: revenue rank 225 of 287, share 0%.

225 / 2870%revenue share

Who dominates this industry?

  1. 1삼성바이오로직스7.3%
  2. 2셀트리온5.7%
  3. 3녹십자홀딩스3.5%
  4. 4유한양행3.3%
  5. 5대웅3.1%
  6. 6에스바이오메딕스0%

Concentration

DistributedCR3 16.6%
HHI 201287 revenue members

HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.

Polarization

Winner-take-all deepeningConsistent

Polarization measures industry gaps and structure, not valuation, forecast, or investment advice.

Margin lens

IQR%p
31.61
Direction
확대
Level
넓음
Years
7

Value lens

P90/P10
14
Median P/B
1.47
Level
넓음
n
263

Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)

Factual information, not investment advice.

Risk sensitivity — adverse assumptions

Metric changes under stated assumptions; not a forecast or investment advice.

Base metrics

Operating margin
-38.4%
Interest coverage
-6.6x
Return on equity (ROE)
-49.1%

Operating margin −5pp

Operating loss
Interest coverageBase -6.6x adverse case -7.5x
Return on equity (ROE)Base -49.1% adverse case -57%

Revenue −15%

Interest coverage risk
Interest coverageBase -6.6x adverse case -5.6x
Return on equity (ROE)Base -49.1% adverse case -44.5%

Interest rate +2pp

Interest coverage risk
Interest coverageBase -6.6x adverse case -3.6x
Return on equity (ROE)Base -49.1% adverse case -56.7%

Interest coverage limit

Already below the limit by 44.2pp

Interest coverage limit at an operating margin of 5.8%

Interest expense coverage threshold

Key suppliers · Annual report

Annual reportDART · 2026-03-24

Suppliers disclosed by the company in its 2026-03-24 annual report.

Suppliers without disclosed amount

FBSDMEMHyaluronic

Financials at a glance

S.Biomedics's latest results and balance sheet. The bars track the last three periods.

Who held it · filings

Filed record

A historical record from curated-guru 13F filings and DART 5%+ major-holding disclosures.

US 13F는 분기 공시이며 최대 45일 뒤 제출될 수 있습니다.

5%+ major-holding disclosures

  • KANG SAEIL22.65%2026-01-09 · 증감 -0.63%p
  • 타이거자산운용투자일임6.85%2026-04-22 · 증감 +6.85%p

Other stocks held by the same investors

A filing-based shared-holder record, not investment advice.

Recent filings

S.Biomedics's latest filings on Korea's DART. Open a headline for a reference summary and the original.

Source: DART (Korea electronic disclosure)

Like these rules? Run them automatically.

Quantus turns rules like these into backtests and automated trading — same team, free to start.

Quantus Signal · live data · not investment advice · Privacy Policy